Detalhe da pesquisa
1.
A CT-based radiomics classification model for the prediction of histological type and tumour grade in retroperitoneal sarcoma (RADSARC-R): a retrospective multicohort analysis.
Lancet Oncol
; 24(11): 1277-1286, 2023 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-37922931
2.
Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma: EORTC-62092 Trial (STRASS) Versus Off-trial (STREXIT) Results.
Ann Surg
; 278(1): 127-134, 2023 Jul 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35833413
3.
Statistical models versus machine learning for competing risks: development and validation of prognostic models.
BMC Med Res Methodol
; 23(1): 51, 2023 02 24.
Artigo
Inglês
| MEDLINE | ID: mdl-36829145
4.
First-line chemotherapy in advanced intra-abdominal well-differentiated/dedifferentiated liposarcoma: An EORTC Soft Tissue and Bone Sarcoma Group retrospective analysis.
Cancer
; 128(15): 2932-2938, 2022 08 01.
Artigo
Inglês
| MEDLINE | ID: mdl-35561319
5.
Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the EORTC 62092-22092 STRASS trial.
Cancer
; 128(14): 2796-2805, 2022 07 15.
Artigo
Inglês
| MEDLINE | ID: mdl-35536104
6.
Exploratory analysis of tumor imaging in a Phase 2 trial with cabozantinib in gastrointestinal stromal tumor: lessons learned from study EORTC STBSG 1317 'CaboGIST'.
Acta Oncol
; 61(6): 663-668, 2022 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-35481400
7.
Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial.
Lancet Oncol
; 21(10): 1366-1377, 2020 10.
Artigo
Inglês
| MEDLINE | ID: mdl-32941794
8.
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Cancer
; 126(11): 2637-2647, 2020 06 01.
Artigo
Inglês
| MEDLINE | ID: mdl-32129883
9.
Association of pazopanib-induced toxicities with outcome of patients with advanced soft tissue sarcoma; a retrospective analysis based on the European Organisation for Research and Treatment of Cancer (EORTC) 62043 and 62072 clinical trials.
Acta Oncol
; 58(6): 872-879, 2019 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-30831041
10.
Prognostic factors for soft tissue sarcoma patients with lung metastases only who are receiving first-line chemotherapy: An exploratory, retrospective analysis of the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Int J Cancer
; 142(12): 2610-2620, 2018 06 15.
Artigo
Inglês
| MEDLINE | ID: mdl-29383713
11.
Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group Trials.
Oncologist
; 23(10): 1250-1259, 2018 10.
Artigo
Inglês
| MEDLINE | ID: mdl-29650688
12.
Do patients whose tumor achieved a pathological response relapse at specific sites? A substudy of the EORTC 10994/BIG-1-00 trial.
Breast Cancer Res Treat
; 169(3): 497-505, 2018 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-29435853
13.
Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.
Acta Oncol
; 57(8): 1117-1126, 2018 Aug.
Artigo
Inglês
| MEDLINE | ID: mdl-29521151
14.
iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.
Lancet Oncol
; 18(3): e143-e152, 2017 03.
Artigo
Inglês
| MEDLINE | ID: mdl-28271869
15.
Predictive and prognostic factors associated with soft tissue sarcoma response to chemotherapy: a subgroup analysis of the European Organisation for Research and Treatment of Cancer 62012 study.
Acta Oncol
; 56(7): 1013-1020, 2017 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-28431480
16.
Reply to Deleterious effect of ifosfamide in leiomyosarcoma: Convergence of weak signals.
Cancer
; 126(20): 4615-4616, 2020 10 15.
Artigo
Inglês
| MEDLINE | ID: mdl-32767667
17.
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072).
Cancer
; 121(17): 2933-41, 2015 Sep 01.
Artigo
Inglês
| MEDLINE | ID: mdl-26033286
18.
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial.
Lancet Oncol
; 15(4): 415-23, 2014 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-24618336
19.
Attitudes of healthcare professionals and drug regulators about progression-free survival as endpoint in the advanced cancer setting.
Eur J Cancer
; 197: 113496, 2024 Jan.
Artigo
Inglês
| MEDLINE | ID: mdl-38134481
20.
EORTC 2238 "De-Escalate": a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors.
Front Oncol
; 14: 1391825, 2024.
Artigo
Inglês
| MEDLINE | ID: mdl-38779087